The imaging of complex cellular structures is central to modern cancer biology, and a state-of-the-art Microscopy Facility is essential to the mission of a Cancer Center. As such, the Wistar Institute has made a strong effort to acquire the necessary instrumentation to accomplish its mission and to have it managed by a highly competent biological imaging specialist, Mr. James Hayden. The Microscopy Facility has served an important role for the members of the Wistar Cancer Center since 1973. Over the past five years, the Facility has grown tremendously and, with changes in scientific focus and the addition of new technologies and instrumentation, has evolved into a premier asset of the Institute and Cancer Center. With new leadership, a reconfiguration of space that improved utilization, new technical applications, new support services, and training at all levels, the Facility has experienced a substantial increase in Cancer Center member usage. Since 2003, thirty-one out of 32 laboratories from all three Cancer Center research programs have used services provided by the Microscopy Facility. Significant scientific accomplishments published in high impact journals have been achieved using new facility equipment, including the Xenogen MS imaging system for in vivo bioluminescent studies of tumor metastases (Huang, Kissil and Pure), the 2 Photon microscopy system to image in vivo movement of immune cells and their interaction with tumor cells (Ertl and Weninger laboratories), and the Live-Cell microscopy system to image in-vitro cell-cell and cell-matrix interactions (M. Herlyn, Heber-Katz, and Pure laboratories). Standard wide-field and confocal microscopy (Lieberman, Maul and Rauscher laboratories) available through the Facility has also aided studies in molecular interactions at the subcellular level. Since the previous renewal, approximately $514,000 was committed by the Institute for new instrumentation and upgrades.
Without the ability to provide expensive high end microscopy instruments, instruction, and support to all Cancer Center members, they would not be able to perform many experiments without purchasing this equipment in their individual labs and this would delay valuable cancer research.
|Tempera, Italo; De Leo, Alessandra; Kossenkov, Andrew V et al. (2016) Identification of MEF2B, EBF1, and IL6R as Direct Gene Targets of Epstein-Barr Virus (EBV) Nuclear Antigen 1 Critical for EBV-Infected B-Lymphocyte Survival. J Virol 90:345-55|
|Nelson, David M; Jaber-Hijazi, Farah; Cole, John J et al. (2016) Mapping H4K20me3 onto the chromatin landscape of senescent cells indicates a function in control of cell senescence and tumor suppression through preservation of genetic and epigenetic stability. Genome Biol 17:158|
|Seo, Jae Ho; Rivadeneira, Dayana B; Caino, M Cecilia et al. (2016) The Mitochondrial Unfoldase-Peptidase Complex ClpXP Controls Bioenergetics Stress and Metastasis. PLoS Biol 14:e1002507|
|Haut, Larissa H; Gill, Amanda L; Kurupati, Raj K et al. (2016) A Partial E3 Deletion in Replication-Defective Adenoviral Vectors Allows for Stable Expression of Potentially Toxic Transgene Products. Hum Gene Ther Methods :|
|Peck, Barrie; Schug, Zachary T; Zhang, Qifeng et al. (2016) Inhibition of fatty acid desaturation is detrimental to cancer cell survival in metabolically compromised environments. Cancer Metab 4:6|
|Chae, Young Chan; Vaira, Valentina; Caino, M Cecilia et al. (2016) Mitochondrial Akt Regulation of Hypoxic Tumor Reprogramming. Cancer Cell 30:257-72|
|Vazquez, Alexei; Kamphorst, Jurre J; Markert, Elke K et al. (2016) Cancer metabolism at a glance. J Cell Sci 129:3367-73|
|Kumar, Vinit; Patel, Sima; Tcyganov, Evgenii et al. (2016) The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment. Trends Immunol 37:208-20|
|Kung, Che-Pei; Murphy, Maureen E (2016) The role of the p53 tumor suppressor in metabolism and diabetes. J Endocrinol 231:R61-R75|
|Patro, Sean C; Azzoni, Livio; Joseph, Jocelin et al. (2016) Antiretroviral therapy in HIV-1-infected individuals with CD4 count below 100 cells/mm3 results in differential recovery of monocyte activation. J Leukoc Biol 100:223-31|
Showing the most recent 10 out of 582 publications